ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, announced that Jaume Pons, Ph.D., Founder, President and Chief Executive Officer and other senior executives, will participate in two virtual investor conferences in November.
BURLINGAME, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that Jaume Pons, Ph.D., Founder, President and Chief Executive Officer and other senior executives, will participate in two virtual investor conferences in November.
29th Annual Credit Suisse Virtual Healthcare Conference
Format: Fireside chat with covering analyst, Martin Auster, M.D.
Date: Monday, November 9
Time: 11:45 AM Eastern Time
Webcast link: Available here
Jefferies Virtual London Healthcare Conference
Format: Fireside chat with covering analyst, Michael Yee
Date: Thursday, November 19
Time: 1:10 PM Eastern Time
Webcast link: Available here
A live webcast of the fireside chats can be accessed by visiting the Investors section of ALX Oncology’s website at www.alxoncology.com and selecting the Investor Calendar under the News and Events tab. A replay of the webcasts will be archived for up to 90 days following the presentation dates.
About ALX Oncology
ALX Oncology is a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. ALX Oncology’s lead product candidate, ALX148, is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. ALX148 has demonstrated promising clinical responses across a range of hematologic and solid malignancies in combination with a number of leading anti-cancer agents. ALX Oncology intends to continue clinical development of ALX148 for the treatment of a range of solid tumor indications and myelodysplastic syndromes. For more information, please visit ALX Oncology’s website at https://www.alxoncology.com.
Investor Contact: Peter Garcia Chief Financial Officer, ALX Oncology (650) 466-7125 Ext. 113 peter@alxoncology.com Argot Partners (212)-600-1902 alxoncology@argotpartners.com Media Contact: Karen Sharma MacDougall (781) 235-3060 alx@macbiocom.com
